The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Real world data of ixazomib in combination with lenalidomide and dexamethasome
Rakesh Popat
• 24 Jun 2017
Ixazomib is a novel oral proteosome inhibitor approved in combination with lenalidomide and dexamethasome for the treatment of relapsed/refractory multiple myeloma. Here, Rakesh Popat, MD, PhD from the University College London, London, UK talks about the real world data presented at European Hematology Association (EHA) 2017 meeting.
